Evidence map›Paper›PMID 41742943›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Emma Robinson, Elisabeth Murphy, Anaseidy Albanez, Sonam Tulsyan, Hong Lou, Yi Xie, Weiyin Zhou, Qian Yang, Tawnjerae Joe, Tongwu Zhang and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Emma RobinsonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Elisabeth MurphyCaris Life Sciences, Irving, TX, USA.
Anaseidy AlbanezInstituto de Cancerología (INCAN), Guatemala City, Guatemala.
Sonam TulsyanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Hong LouCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Yi XieDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Weiyin ZhouCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Qian YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Tawnjerae JoeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Tongwu ZhangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Jia LiuCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Wen LuoCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Dongling WuCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Herbert HigsonCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Mathias ViardBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA, and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Mary CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA, and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Matt OberleyCaris Life Sciences, Irving, TX, USA.
Douglas R StewartDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Hesler MoralesInstituto de Cancerología (INCAN), Guatemala City, Guatemala.
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Enrique AlvirezHospital Central Universitario "Dr. Antonio M Pineda," Barquisimeto, Lara State, Venezuela, and Universidad Andino de Cusco, Cusco, Perú.
Roberto OrozcoHospital General San Juan de Dios, Guatemala City, Guatemala.
Eduardo GharzouziIntegra Cancer Center, Guatemala City, Guatemala.
Michael DeanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0003-2234-0631

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Between 10 and 20% of cervical cancers are adenocarcinomas with poorer five-year survival and higher recurrence. To identify somatic alterations driving cervical cancer, we performed whole-exome sequencing of 308 subjects with invasive disease from Guatemala and Venezuela. Consistent with other studies, there is a higher rate of

Indexed as

adenocarcinomaCervical cancerhuman papilloma virusSTK11 oncogenewhole exome sequencing

Identifiers

PMID41742943
PMCPMC12930441

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.